A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas (NCT05463263)
An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
🩺 Plain-English Summary (8th-Grade Level)
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Who can join: Review the eligibility criteria below.
Location: Colorado Blood Cancer Institute — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Colorado Blood Cancer Institute — Denver, Colorado
- Florida Cancer Specialists — Sarasota, Florida
- Memorial Sloan Kettering — New York, New York
- Hôpital Saint-Louis — Paris, Paris
- The Centre Léon Bérard — Lyon,
- Institut Paoli Calmettes — Marseille,
- CHU de Nantes — Nantes,
- Institut Gustave Roussy — Villejuif,
- University Hospitals of Leicester NHS Trust — Leicester,
- Imperial College / Clinical Trials Unit, Hammersmith Hospital — London,
- The Christie — Manchester,
- Nottingham City Hospital — Nottingham,
- Churchill Hospital — Oxford,
- Derriford Hospital — Plymouth,
- The Royal Marsden — Sutton,
📞 Contact the Study Coordinator
Phone: +33 1 86 26 43 56
Email: STP938-101@step-ph.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, B-Cell
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) — Scottsdale, Arizona
- FT819 in Subjects With B-cell Malignancies — Birmingham, Alabama
- Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma — Vancouver, British Columbia
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — Burbank, California
- Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma — Birmingham, Alabama
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers — New York, New York
Explore by condition: All Lymphoma, B-Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.